JP2020033360A5 - - Google Patents

Download PDF

Info

Publication number
JP2020033360A5
JP2020033360A5 JP2019186952A JP2019186952A JP2020033360A5 JP 2020033360 A5 JP2020033360 A5 JP 2020033360A5 JP 2019186952 A JP2019186952 A JP 2019186952A JP 2019186952 A JP2019186952 A JP 2019186952A JP 2020033360 A5 JP2020033360 A5 JP 2020033360A5
Authority
JP
Japan
Prior art keywords
deoxygalactonojirimycin
salt
gal
therapeutic agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019186952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020033360A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020033360A publication Critical patent/JP2020033360A/ja
Publication of JP2020033360A5 publication Critical patent/JP2020033360A5/ja
Priority to JP2021018456A priority Critical patent/JP2021098697A/ja
Pending legal-status Critical Current

Links

JP2019186952A 2011-03-11 2019-10-10 ファブリー病の治療用投薬レジメン Pending JP2020033360A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021018456A JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US61/451,798 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US61/578,201 2011-12-20
US201261596165P 2012-02-07 2012-02-07
US61/596,165 2012-02-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017038469A Division JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021018456A Division JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン

Publications (2)

Publication Number Publication Date
JP2020033360A JP2020033360A (ja) 2020-03-05
JP2020033360A5 true JP2020033360A5 (https=) 2020-04-23

Family

ID=46831259

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013557862A Pending JP2014528901A (ja) 2011-03-11 2012-03-08 ファブリー病の治療用投薬レジメン
JP2017038469A Pending JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン
JP2019186952A Pending JP2020033360A (ja) 2011-03-11 2019-10-10 ファブリー病の治療用投薬レジメン
JP2021018456A Withdrawn JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン
JP2023045001A Pending JP2023093448A (ja) 2011-03-11 2023-03-22 ファブリー病の治療用投薬レジメン
JP2025179237A Pending JP2026035578A (ja) 2011-03-11 2025-10-24 ファブリー病の治療用投薬レジメン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013557862A Pending JP2014528901A (ja) 2011-03-11 2012-03-08 ファブリー病の治療用投薬レジメン
JP2017038469A Pending JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021018456A Withdrawn JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン
JP2023045001A Pending JP2023093448A (ja) 2011-03-11 2023-03-22 ファブリー病の治療用投薬レジメン
JP2025179237A Pending JP2026035578A (ja) 2011-03-11 2025-10-24 ファブリー病の治療用投薬レジメン

Country Status (16)

Country Link
US (4) US20140219986A1 (https=)
EP (2) EP3698792A1 (https=)
JP (6) JP2014528901A (https=)
KR (1) KR20140011367A (https=)
CN (2) CN107088225A (https=)
AU (6) AU2012229330B2 (https=)
CA (1) CA2829947C (https=)
CL (1) CL2013002601A1 (https=)
EA (1) EA031874B1 (https=)
ES (1) ES2807502T3 (https=)
HK (1) HK1242998A1 (https=)
MX (1) MX2013010446A (https=)
SG (2) SG10201604757RA (https=)
TW (3) TWI624259B (https=)
WO (1) WO2012125402A2 (https=)
ZA (1) ZA201306735B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
EP3108002A1 (en) * 2014-02-17 2016-12-28 GlaxoSmithKline Intellectual Property Development Limited Microbiological process
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017027709A1 (en) 2015-08-11 2017-02-16 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
KR20190087673A (ko) * 2016-03-22 2019-07-24 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
EP3539033B1 (en) 2016-11-14 2024-10-02 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
CA3053245A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
RS65230B1 (sr) * 2017-05-30 2024-03-29 Amicus Therapeutics Inc Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
KR20200128676A (ko) * 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽
MX2021015352A (es) * 2019-06-11 2022-04-06 Amicus Therapeutics Inc Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
AU2020343020A1 (en) 2019-09-06 2022-03-31 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat
TR2024011149A1 (tr) * 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
TR2024011147A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonu

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2857036B1 (en) * 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
PL2533050T6 (pl) * 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
MX2009010557A (es) * 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
WO2009032171A1 (en) * 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a

Similar Documents

Publication Publication Date Title
JP2020033360A5 (https=)
JP2020073529A5 (https=)
JP2015519329A5 (https=)
ES3029536T3 (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
JP2014528901A5 (https=)
ES2762250T3 (es) Tratamiento combinado del cáncer
ES2617628T3 (es) Régimen de dosificación para un agonista selectivo del receptor de S1P1
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2016516016A5 (https=)
JP2010526101A5 (https=)
ES3060357T3 (en) Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2017510607A5 (https=)
JP2021512896A5 (https=)
JP2018509419A5 (https=)
JP2020536121A5 (https=)
JP2020529440A5 (https=)
IL292770A (en) Formulations and dosages of polyethylene glycol-modified oricase
JP2020500864A5 (https=)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2015522077A5 (https=)
ES3062720T3 (en) Sublingual epinephrine tablets
JP2016505050A5 (https=)
JP2008517991A5 (https=)
ES2773711T3 (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos